Grapsum Healthcare Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 30-06-2024
- Paid Up Capital ₹ 2.50 M
as on 30-06-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.08 M
as on 30-06-2024
- Revenue -70.48%
(FY 2022)
- Profit -89.50%
(FY 2022)
- Ebitda -354.79%
(FY 2022)
- Net Worth -59.94%
(FY 2022)
- Total Assets -0.39%
(FY 2022)
About Grapsum Healthcare
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹2.08 M.
Nimisha Pare and Shailendra Pare serve as directors at the Company.
- CIN/LLPIN
U24233MP2011PTC026051
- Company No.
026051
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 May 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Grapsum Healthcare Private Limited offer?
Grapsum Healthcare Private Limited offers a wide range of products and services, including Bird Food, Poultry & Animal Food, Animal Feed Supplement, Ayurvedic Herbal Syrups & Tonics, Ayurvedic Health Tonic, Cough Syrup, Aloe Vera Cosmetics, Aloe Vera Gel, Homeopathic Medicines & Remedies, Homeopathic Drugs, Ayurvedic Digestive Medicine.
Who are the key members and board of directors at Grapsum Healthcare?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nimisha Pare  | Director | 01-Sep-2012 | Current |
| Shailendra Pare | Director | 24-May-2011 | Current |
Financial Performance of Grapsum Healthcare.
Grapsum Healthcare Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 70.48% decrease. The company also saw a substantial fall in profitability, with a 89.5% decrease in profit. The company's net worth observed a substantial decline by a decrease of 59.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Grapsum Healthcare?
In 2021, Grapsum Healthcare had a promoter holding of 18.80% and a public holding of 81.20%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 31 May 2014 | ₹2.08 M | Open |
How Many Employees Work at Grapsum Healthcare?
Unlock and access historical data on people associated with Grapsum Healthcare, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Grapsum Healthcare, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Grapsum Healthcare's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
